View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals
February 3, 2022

Equity offerings drop in clinical trial operations in H2

Where the deal value was known, the highest value equity offering announced in 2021 is the financing to be raised by Asymchem Laboratories in an IPO of shares.

By Data Journalism Team

In the second half of 2021 the number of equity offerings decreased significantly by 21.7% from the same period in 2020.

This marks a deceleration in growth from the 11.5% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

During this time, the region that saw the biggest increase in the number of deals was The Asia-Pacific region.

From the second half of 2020 to the second half of 2021, the largest regional increase in deals was also seen in The Asia-Pacific region.

During second half of 2021, equity offerings accounted for 2.8% of all deals taking place in the sector. This represents an increase from the figure of 1.4% in second half of 2020.

GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.

The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.

By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.

The highest value equity offering announced in 2021 (where the deal value was known), is the financing to be raised by Asymchem Laboratories in an IPO of shares. The deal is set to be worth $968m.

The database states that the rationale behind this deal was as follows: "The company intends to use the proceeds for business expansion, R&D and to meet working capital needs."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU